Cell Therapy News/Articles, page-57

@tubbyguts

That's a good point.

AusBiotech signed a memorandum of understanding (MoU) with Japan’s peak regenerative medicine body, Forum for Innovative Regenerative Medicine (FIRM mid-Oct 2017) under the MoU between Australian Trade Commission (Austrade) and FIRM, in relation to the collaboration in advancing regenerative medicine and cell and gene therapies within Australia, Japan and worldwide.

FIRM is a Japanese general incorporated association with a mission to accelerate research and commercialization of regenerative medicine in Japan. FIRM was formed in 2011 and has more than 220 members of Japanese companies from various fields with diverse expertise in such as pharmaceutical, biotechnology, manufacturing, transportation, insurance and related supporting areas for regenerative medicine.

AusBiotech and FIRM will collaborate in advancing their individual and common missions by sharing information, encompassing technology, policy, laws, etc, and assist each other in co-sponsoring meetings or through other cooperation based on common concerns.

In particular, AusBiotech sees FIRM as an important international partner and the representative of the regenerative medicine industry in Japan, and FIRM sees AusBiotech as an important international partner and the representative of the regenerative medicine industry in Australia.

The FIRM MoU builds on commitments with Korea’s Council for Advanced Regenerative Medicine (CARM), signed last year, to advance regenerative medicine capabilities and indicates that collaboration is essential to leveraging our combined innovative potential.

Silviu will be presenting at Ausbiotech National Conference 2017 this Wednesday 25th October as a keynote speaker at 9.50am in Adelaide

http://ausbiotechnc.org/program-2/program